NCT01671280

Drug Use Investigation Of Azithromycin IV For Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)

Drug Use Investigation Of Azithromycin Iv

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 403 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

To collect the efficacy and safety information of Azithromycin IV related to their appropriate use in daily practice

Conditions

• Pneumonia
• Pelvic Inflammatory Disease

Interventions

Type	Name	Description
DRUG	Azithromycin IV	The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy. The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy.

Timeline

• Start date: 2012-09-20
• Primary completion: 2016-04-22
• Completion: 2016-04-22
• First posted: 2012-08-23
• Last updated: 2017-04-26
• Results posted: 2017-04-26